Medivir Ab

Tibotec Pharmaceuticals Ltd.

Janssen R&d Ireland

Janssen Sciences Ireland Uc

Medivar Ab

Tibotec Bvba

Janssen Products, LP

Tibotec Pharmaceuticals Ltd. Co

Medivir Aktiebolag

Karl Magnus Nilsson

Pierre Jean-Marie Bernard Raboisson

Herman Augustinus De Kock

Kenneth Simmen

Bengt Bertil Samuelsson

Åsa Annica Kristina Rosenquist

Lili Hu

Abdellah Tahri

Dominique Louis Nestor Ghislain Surleraux

Sandrine Marie Helene Vendeville

Per-Ola Mikael Johansson

Vladimir Kirillovich Ivanov

Mikael Pelcman

Anna Karin Gertrud Linnea Belfrage

Dmitry Antonov

Björn Olof Classon

Anna Karin Gertrud Linea Belfrage

Pia Kahnberg

Hans Kristian Wallberg

Lourdes Salvador Odén

Carl Erik Daniel Jönsson

Mats Stefan Lindström

Karin Charlotta Lindquist

Susana Ayesa Alvarez

Horst Jürgen Wähling

Tim Hugo Maria Jonckers

David Craig McGowan

Koen Vandyck

Bertil Samuelsson

Wim Van De Vreken

Horst Wahling

David Craig Mc Gowan

Anna Winqvist

Pierre Jean-Marie Bernard Rabiosson

Ismet Dorange

Pedro Manuel Passos Pinho

Bengt Christian Sund

Michael Pelcman

Vladimir Ivanov

Yvan Simonnet

Anna Karin Belfrage

Sven Crister Sahlberg

Bengt Bertril Samuelsson

Kenneth Alan Simmen

Horst Jürgen WÄHLING

ÅSa Annica Kristina Rosenquist

Pia Cecilia Kahnberg

Åsa Annica Kristina Rosenquist

Inhibitors of HCV replication of formula (I) 

Macrocyclic inhibitors of hepatitis C virus

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond;

Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.

Pyrimidine substituted macrocyclic HCV inhibitors

Inhibitors of HCV replication of formula (I) the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by) represents an optional double bond;

Compounds of formula I: including any possible stereoisomers thereof, wherein:

Phosphoramidate derivatives of nucleosides

HCV inhibiting macrocyclic phenylcarbamates

Macrocylic inhibitors of hepatitis C virus

Macrocylic compounds having inhibitory activity on the replication of the hepatitis C virus (HCV) of the general formula (I) 

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.

Growing community of inventors

Göteborg, Sweden

Karl Magnus Nilsson